Renal Cell Carcinoma

Naomi B. Haas, MD, discusses how patient characteristics and preference influence the choice of frontline treatment for advanced clear cell renal cell carcinoma.

At a live virtual event, Robert J. Motzer, MD, discussed the risk factors for classifying patients with advanced renal cell carcinoma and data from several phase 3 trials of combination regimens.

Eric Jonasch, MD, further discussed the 2 posters he presented in regard to belzutifan at 2022 ASCO.

During a Targeted Oncology case-based roundtable event, Chandler Park, MD, discussed the preferred first-line treatment options including tyrosine kinase inhibitor/immunotherapy combinations for metastatic clear cell renal cell carcinoma.

Following a study of frontline pembrolizumab plus axitinib or nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma, investigators recommended that prospective real-world studies are needed to confirm the results.

Data regarding the triplet combination of nivolumab, ipilimumab, and cabozantinib show clinical activity across multiple tumor types, giving a preview of future outcomes in patients with untreated, advanced renal cell carcinoma.

Results from the phase 3 CLEAR trial showed lenvatinib plus everolimus to have a statistically significant improvement in progression-free survival and objective response rate compared with those given sunitinib.

Decreased risk of disease progression or death on second-line therapy with the combination of lenvatinib and pembrolizumab vs sunitinib in the CLEAR clinical trial.

During a Targeted Oncology case-based roundtable event, Chung-Han Lee, MD, PhD, discussed the use of approved combination regimens including tyrosine kinase inhibitors and immune checkpoint inhibitors for a patient with clear cell renal cell carcinoma.

Results from the phase 3 EVEREST trial presented during the 2022 ASCO Annual Meeting reveal the relapse-free survival advantage of using adjuvant everolimus over placebo in patient with high-risk renal cell carcinoma.

During a live virtual event, Brian Rini, MD, discussed how the combination of cabozantinib plus nivolumab compares with lenvatinib plus pembrolizumab in terms of tolerability and management in patients with advanced renal cell carcinoma.

Toni K. Choueiri, MD, discusses the design of the phase 3 LITESPARK-022 study, which investigates adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.

During a Targeted Oncology case-based roundtable event in Texas, Eric Jonasch, MD, moderated a discussion around the management of clear cell renal cell carcinoma in a 59-year-old African American female patient.

During a live virtual event, Brian Rini, MD, discussed the efficacy and tolerability of approved first-line tyrosine kinase inhibitor and immunotherapy combinations for patients with advanced renal cell carcinoma.

Neoadjuvant axitnib demonstrated significant reductions in tumor size and complexity, allowing for partial nephrectomy in a subgroup of patients with renal cell carcinoma.

Nazli Dizman, MD, discusses what community oncologists should keep in mind about gut microbiome when treating their patients.

During a Targeted Oncology case-based roundtable event, Brian Rini, MD, discussed the choice of treatment options including dual immunotherapy and tyrosine kinase inhibitors plus immunotherapy for a patient with stage IV clear cell renal cell carcinoma.

Thomas Hutson, MD, PharmD, discusses management strategies when confronting adverse events using combination therapies in treating patients with renal cell carcinoma.

Scott S. Tykodi, MD, PhD, and Ulka N. Vaishampayan, MBBS, discussed treatment for patients with relapsed and late-stage renal cell carcinoma based on National Comprehensive Cancer Network guidelines and recent clinical trials.

During a Targeted Oncology case-based roundtable event, Thomas Hutson, DO, PharmaD, discussed immunotherapy and tyrosine kinase inhibitor combinations for frontline therapy of renal cell carcinoma.

PIVOT-09 trial examining bempegaldesleukin plus nivolumab in patients with renal cell carcinoma and bladder cancer has been discontinued.

In an interview, Rana McKay, MD, discussed findings from a real-world study on genomic alterations of metastases in renal cell carcinoma, further research in the field, and findings from the phase 1/2 COMRADE trial in patients with metastatic castration-resistant prostate cancer.

Results from the BIONIKK study confirm that response to immune checkpoint inhibitor monotherapy or combination therapy as well as to VEGFR tyrosine kinase inhibitor therapy is different depending on the characteristics of the tumor and its microenvironment.

In an interview with Targeted Oncology, Viktor Grünwald, MD, discussed the newest updates and advances in RCC and what the current space looks like.

Matthew T. Campbell, MD, discusses the unmet needs for patients with renal cell carcinoma and sarcomatoid dedifferentiation.